



AHMEDABAD
23.5.2010

PRESS RELEASE

Audited financial results for the year ended 31.3.2010

-
- 1. The company registers a growth of 27.39% in Net Profit on a 24.44% growth in Sales over last year.**
 - 2. Recommends 30% dividend for the year 2009-2010.**
-

Hester's Net Profit for the year ended 31.3.2010 is recorded at Rs. 60.33 million, as against Rs. 47.36 million for the previous year.

Hester's cash profit (NP + Depreciation) for the year ended 31.3.2010 is recorded at Rs. 102.66 million, as against Rs. 85.80 million for the previous year.

The company's turnover is Rs. 375.32 million for the year ended 31.3.2010, as compared to a turnover of Rs. 301.60 million for the year ended 31.3.2009.

Earnings Per Share is at Rs. 11.62. as on 31.3.2010 as against Rs. 9.12 as on 31.3.2009.

The large animal vaccine (other than existing poultry vaccines) division of the company is already in the process of developing 3 vaccines which would be released in the current financial year.

The board has approved expansion programs for setting up:

1. A manufacturing unit for animal diagnostic reagents
2. R&D centre in India for animal disease surveillance

The total outlay for this expansion would be approximately Rs. 250 million

The board has recommended a dividend of Rs. 3. per equity share of Rs. 10.00 each (30%), for the financial year 2009-2010, subject to the approval at the ensuing AGM.

Rajiv Gandhi
CEO & Managing Director
Hester Biosciences Limited
www.hesterbiosciences.co.in
rajiv@hesterbiosciences.co.in

Hester Biosciences Limited
Formerly Hester Pharmaceuticals Limited

16/10 Devendra Society, Naranpura, Ahmedabad 380013, India
Ph +91 (0)79 27680476 www.hesterbiosciences.co.in
Fax +91 (0)79 27681231 mail@hesterbiosciences.co.in

Registered Office:

Village Merda Ardraj
Taluka Kadi
District Mehsana
Gujarat 382 721